GenePOC Announces an Exclusive Distribution Agreement with Cardinal Health Covering the US Market

Wednesday, June 28, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

GenePOC announces the signing of an exclusive distribution agreement with Cardinal Health to become its commercial partner in the United States

QUEBEC, June 28, 2017 /PRNewswire/ --

GenePOC, Inc. (GenePOC), a member of the Debiopharm Group, is proud to

announce that it has signed an exclusive distribution agreement with Cardinal Health to become its commercial partner in the United States to sell the revogene™ instrument and associated GenePOC™ assays. This is a key milestone in the development of GenePOC's commercial operations.

"We are extremely proud to announce this collaboration," said Patrice Allibert, CEO of GenePOC, he continued, "Cardinal Health is the perfect match for GenePOC, holding an impressive track record in improving patient life and laboratory efficiency. The GenePOC solution represents a unique market breakthrough, addressing untapped increasing demand for the use of Molecular Testing in a wide range of clinical and laboratory settings. We are confident that this new partnership will support us in making a real difference in the diagnosis of infectious diseases by being closer to the patient. We further believe this distribution agreement will pave the way for GenePOC to become a key Molecular Testing player in the mid-size molecular lab, the satellite lab, and all the way into the Point of Care market."

The revogene™ is a fully-automated, portable standalone instrument. It enables testing of single-use microfluidic cartridges, or PIEs, with its proprietary fluorescence-based quantitative polymerase chain reaction (qPCR) platform to deliver an accurate diagnosis.

Both the revogene™ instrument and it's first to market GenePOC™ GBS LB assay recently received FDA clearance.

About GenePOC 

GenePOC is a company that specializes in the development of diagnostic devices which enable the prevention and detection of infectious diseases.

The company aims to become the market leader in the rapid microbial testing at the point of care (POC). GenePOC is a member of the Debiopharm Group.

GenePOC's revogene™ instrument is available in the US, European and Middle Eastern markets with a rapidly expanding test menu.

Further information: http://www.genepoc-diagnostics.com

About Debiopharm Group 

Debiopharm Group™ is a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management.

For more information, please see http://www.debiopharm.com 

We are on Twitter. Follow @DebiopharmNews at http://twitter.com/DebiopharmNews

Contact at Debiopharm International SA Christelle Tur Communications Coordinator [email protected] Tel.: +41(0)21-321-01-11     Contact at GenePOC Patrice Allibert, Ph.D CEO [email protected] Tel.: +1-418-650-3535

SOURCE Debiopharm International SA



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store